B7-H3 Antibody / CD276 [Clone B7H3/4345] (Purified)

Immunohistochemistry (FFPE): 1-2ug/ml

Optimal dilution of the CD276 antibody should be determined by the researcher.

T cell activation and immune function are regulated by the innate immune system through positive and negative costimulatory molecules. One such molecule, B7-H3 (B7-homolog 3, also designated B7RP-2 and CD276) belongs to the B7 immunoglobulin superfamily. Soluble B7-H3/CD276 binds a putative receptor on activated T-cells that is distinct from CD28, CTLA-4, ICOS and PD-1. Widely expressed on nonlymphoid tissues, it costimulates proliferation of both CD4+ and CD8+ T cells. The ability of B7-H3/CD276 to stimulate Th1 and cytotoxic-T cell responses suggest that it may have antitumor activity. B7-H3 interactions may play a role in regulating cell-mediated immune responses against cancer, implicating B7-H3/CD276 as a potential therapeutic tool.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide

A portion of amino acids 100-300 from the human CD276 protein was used as the immunogen for the CD276 antibody.

This CD276 antibody is available for research use only.

Cell surface, cytoplasm

Protein A/G affinity

Q5ZPR3